0001104659-26-027751
SEC filingAnnovis Bio, Inc. reported a net loss of $28.9 million for fiscal year 2025, an increase from a $24.6 million net loss in 2024. The company generated no revenue and incurred total operating expenses of $29.7 million, primarily driven by research and development costs of $25.2 million for its Phase 3 Alzheimer's disease trial and other clinical programs. Cash used in operating activities was $25.6 million, but net cash increased by $9.0 million to $19.5 million at year-end due to $34.6 million in financing activities from equity offerings. The company's accumulated deficit reached $163.7 million, and management expressed substantial doubt about the company's ability to continue as a going concern beyond the third quarter of 2026 without additional capital.
Annovis Bio reported a net loss of $28.9 million for fiscal year 2025, compared to a net loss of $24.6 million in 2024, representing a 17.3% increase in losses. The company generated no revenue during either period. Total operating expenses were $29.7 million in 2025, up from $26.7 million in 2024. Research and development expenses increased by $5.2 million to $25.2 million, primarily due to costs associated with the Phase 3 Alzheimer's disease trial initiated in February 2025. General and administrative expenses decreased by $2.2 million to $4.5 million, mainly due to reduced stock-based compensation. The company reported other income of $841,000, consisting of interest income of $699,000 and a change in fair value of warrants of $142,000.
The company is a clinical-stage biopharmaceutical company with no approved products and therefore generated no revenue during fiscal year 2025. All operations are focused on research and development of buntanetap for Alzheimer's disease and Parkinson's disease. The company operates as a single segment with all assets located in the United States. The business model relies entirely on equity financing to fund clinical development activities, with no product sales or licensing revenue currently generated.
As a pre-revenue company, Annovis Bio reported negative operating margins with an operating loss of $29.7 million in 2025. The company's cost structure is dominated by research and development expenses, which represented 85% of total operating expenses. Research and development expenses increased primarily due to clinical trial costs for the Phase 3 Alzheimer's disease study, partially offset by decreased manufacturing costs and statistical work. General and administrative expenses decreased due to reduced stock-based compensation and corporate legal costs. The company has never been profitable and has incurred net losses since inception in 2008.
Cash used in operating activities was $25.6 million in 2025, compared to $21.9 million in 2024. The company reported cash and cash equivalents of $19.5 million as of December 31, 2025, up from $10.5 million at the end of 2024. Net cash provided by financing activities was $34.6 million, primarily from equity offerings including a $19.3 million underwritten offering with ThinkEquity in February 2025. Total assets were $21.1 million, with total liabilities of $4.2 million and stockholders' equity of $16.9 million. The accumulated deficit reached $163.7 million. Management expressed substantial doubt about the company's ability to continue as a going concern beyond the third quarter of 2026 without additional financing.
The company expects to incur significant operating losses for the foreseeable future as it continues clinical development. Current cash is expected to fund operations only into the third quarter of 2026. The company plans to raise substantial additional capital through public or private equity offerings, debt financings, or collaboration arrangements to complete development and commercialization of buntanetap. Key upcoming milestones include the 6-month symptomatic component readout for the Phase 3 AD trial expected in the second half of 2026 and the 18-month disease-modifying component expected in the second half of 2027. The company also plans to initiate a Phase 3 trial for Parkinson's disease dementia contingent on additional funding. Major risk factors include the need for additional financing, clinical trial outcomes, regulatory approvals, and competition in neurodegenerative disease treatments.